RECOVER: sequential model optimization platform for combination drug
  repurposing identifies novel synergistic compounds in vitro
  Selecting optimal drug repurposing combinations for further preclinical
development is a challenging technical feat. Due to the toxicity of many
therapeutic agents (e.g., chemotherapy), practitioners have favoured selection
of synergistic compounds whereby lower doses can be used whilst maintaining
high efficacy. For a fixed small molecule library, an exhaustive combinatorial
chemical screen becomes infeasible to perform for academic and industry
laboratories alike. Deep learning models have achieved state-of-the-art results
in silico for the prediction of synergy scores. However, databases of drug
combinations are highly biased towards synergistic agents and these results do
not necessarily generalise out of distribution. We employ a sequential model
optimization search applied to a deep learning model to quickly discover highly
synergistic drug combinations active against a cancer cell line, while
requiring substantially less screening than an exhaustive evaluation. Through
iteratively adapting the model to newly acquired data, after only 3 rounds of
ML-guided experimentation (including a calibration round), we find that the set
of combinations queried by our model is enriched for highly synergistic
combinations. Remarkably, we rediscovered a synergistic drug combination that
was later confirmed to be under study within clinical trials.
